Loading
institutionsInstitution
Translational Genomics Research Institute (TGen)
Arizona genomics institute, part of City of Hope, whose pancreatic cancer programme under Daniel Von Hoff produced the MPACT trial that established nab-paclitaxel plus gemcitabine.
Also called: TGenCity of Hope TGenHonorHealth Research Institute
Overview
The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute in Phoenix, an affiliate of City of Hope since 2016. Its clinical programme, run with the HonorHealth Research Institute in Scottsdale, was led by Daniel Von Hoff, who was first author of the 2013 New England Journal of Medicine report of MPACT, in which nab-paclitaxel plus gemcitabine lengthened survival in metastatic pancreatic cancer. TGen also runs precision medicine programmes in paediatric cancer and glioblastoma.
Location
Phoenix, AZ, US
Type
research institute
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#700 · 2 points (0 Newsweek + 0 NCI + 2 from 1 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Translational Genomics Research Institute, including child institutions. 100 works · 2,024 citations · 69% open access · 19% clinical trials · 1% reviews.
Oncology works per year
192022
192023
312024
162025
152026
Most works
- Daniel D. Von Hoff26 works
- Haiyong Han21 works
- Erkut Hasan Borazanci15 works
- Luis Alfredo Meza13 works
- Stephen J. Forman12 works
- Sumanta Kumar Pal12 works
- Behnam Badie12 works
- Gayle Jameson11 works
- Zeynep Büşra Zengin11 works
- Derek Cridebring11 works
Most cited
- Pancreatic cancer
- Precision medicine
- Paediatric genomics
Similar pages
- Key paperMPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer
Shares Daniel D. Von Hoff, Pancreatic ductal adenocarcinoma.
- TrialMPACT
Shares Daniel D. Von Hoff, Pancreatic ductal adenocarcinoma.
- Key paperNanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Shares Daniel D. Von Hoff, Pancreatic ductal adenocarcinoma.